✦ LIBER ✦

Duplication of the Ph-chromosome as a possible mechanism of resistance to imatinib mesylate in patients with chronic myelogenous leukemia

✍ Scribed by A. Ossard-Receveur; A. Bernheim; B. Clausse; G. Danglot; D. Fauvet; B. Leon; F. Lozach; D. Bories; C. Brouzes; J.H. Bourhis; A.G. Turhan

Book ID: 113512738
Publisher: Elsevier Science
Year: 2005
Tongue: English
Weight: 60 KB
Volume: 163
Category: Article
ISSN: 0165-4608
DOI: 10.1016/j.cancergencyto.2005.05.004

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

P-glycoprotein-mediated drug efflux is a

P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate

✍ Illmer, T; Schaich, M; Platzbecker, U; Freiberg-Richter, J; Oelschlägel, U; von 📂 Article 📅 2004 🏛 Nature Publishing Group 🌐 English ⚖ 296 KB

Masked Ph chromosome due to a new type o

Masked Ph chromosome due to a new type of translocation in a patient with chronic myelogeneous leukemia

✍ Ikuo Miura; Keiko Hashimoto; Tamio Nishinari; Akira B. Miura; Kazuo Komatsu; Emi 📂 Article 📅 1988 🏛 Elsevier Science 🌐 English ⚖ 161 KB

Phase II study of troxacitabine, a novel

Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase

✍ Francis J. Giles; Eric J. Feldman; Gail J. Roboz; Richard A. Larson; Steven W. M 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 72 KB

Prediction of initial cytogenetic respon

Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia

✍ Mark W. Drummond; Tessa L. Holyoake 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 80 KB 👁 1 views

Prediction of initial cytogenetic respon

✍ Hagop Kantarjian; Moshe Talpaz; Susan O'Brien; Francis Giles; Mary Beth Rios; Ke 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 76 KB 👁 1 views

## Abstract ## BACKGROUND Obtaining a major (Philadelphia chromosome [Ph] of < 35%) or a complete cytogenetic response (Ph of 0%) has been associated with excellent long‐term survival. Cytogenetic response may continue to improve with therapy. Because early allogeneic stem cell transplantation (SC

PCN72 Modeling the Survival Loss in Pati

PCN72 Modeling the Survival Loss in Patients With Philadelphia Chromosome Positive (Ph+) Chronic Phase Chronic Myeloid Leukemia (CML-CP) Switched from Imatinib Mesylate to a Generic Copy

✍ M. Botteman; M. Magestro; A.F. Alwan 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB